Celanese Exhibits Tribological Medical Device Materials

Zacks

Celanese Corporation CE is presenting its tribological medical polymer solutions at the ongoing 2015 Annual Pre-filled Syringes Summit in Berlin, Germany.

Tribological systems in pre-filled syringes and other medical devices are sophisticated applications which require innovative materials that Celanese provides. These medical devices must be safe and comfortable for the patient and Celanese ensures the same by providing its innovative and advanced polymer materials for the development of these devices.

Celanese will present new technical data and discuss Hostaform MT SlideX POM, its tribological polymer grade for the medical device market.

In the second quarter of 2015, Celanese's adjusted earnings topped the Zacks Consensus Estimate, aided by healthy margins in the Materials Solutions business. Revenues, however, fell by double digits and missed expectations. The company has raised its adjusted earnings forecast for 2015.

The company is confident that it can drive performance through the rest of 2015 despite currency headwinds and a challenging macro environment, especially the recent volatility in China. Celanese expects to offset these headwinds with strong operating performance across all its segments and higher productivity gains.

Celanese currently carries a Zacks Rank #2 (Buy).

Some other favorably ranked stocks in the chemical space include Koppers Holdings Inc. KOP, Arkema S.A. ARKAY and Marrone Bio Innovations, Inc. MBII. While Koppers and Arkema sport a Zacks Rank #1 (Strong Buy), Marrone Bio Innovations carries a Zacks Rank #2.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

Be the first to comment

Leave a Reply